SGO 2021: GynOnc
Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer

Released: April 07, 2021

Expiration: April 06, 2022

Jubilee Brown
Jubilee Brown, MD
Ursula Matulonis
Ursula Matulonis, MD

Activity

Progress
1
Course Completed

In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including:

  • Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancer
  • Results from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer
  • 5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian cancer
  • Long-term follow-up results from the phase III ENGOT-OV16/NOVA trial of niraparib in patients with recurrent ovarian cancer
  • OPAL: a phase II study evaluating dostarlimab, bevacizumab, and niraparib in platinum-resistant ovarian cancer

Presenters:

Jubilee Brown, MD
Professor and Director of Gynecologic Oncology
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts